

# ***BIOCHEMICAL NEUROLOGY***

***M. J. Eadie and J. H. Tyrer***

# **BIOCHEMICAL NEUROLOGY**

***M. J. Eadie and J. H. Tyrer***

*Department of Medicine  
University of Queensland  
Brisbane, Australia*



**MTP PRESS LIMITED · LANCASTER · ENGLAND**  
*International Medical Publishers*

Published in the UK and Europe by  
MTP Press Limited  
Falcon House  
Lancaster, England

**British Library Cataloguing in Publication Data**

Eadie, M. J.

Biochemical neurology.

1. Neurochemistry

I. Title

II. Tyrer, J. H.

612'.8042

QP356.3

ISBN 0-85200-494-X

Copyright © 1983 M. J. Eadie and J. H. Tyrer

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the publishers.

Filmset by Northumberland Press Ltd, Gateshead  
Printed by McCorquodale (Scotland) Ltd.

# Preface

... it is probable that by the aid of chemistry many derangements of the brain and mind, which are at present obscure, will become accurately definable.'

J. L. W. Thudichum (1884) *Chemical Constitution of the Brain*.

Dysfunction of the human nervous system may be interpreted at different levels of the system's own organizational complexity. For centuries neurological disorders had to be assessed mainly by means of the unaided human senses. In the present century, light and electron microscopy have opened the way to an understanding of neurological disorder at a cellular and subcellular level, while electronic amplification devices have permitted the study of nervous system dysfunction at an electrophysiological level. In recent years there has been increasing investigation of both normal and abnormal neural function at its ultimate level, the molecular or chemical one. In the last analysis, all dysfunction of the nervous system must somewhere involve alterations in its component molecules. At present it is not possible to provide a complete account of all molecular changes which must occur in the various neurological diseases. However, biochemical knowledge of neurological disorders has grown rapidly and sufficient material is now available for a moderately coherent biochemical interpretation of many neurological diseases. In the past, when neurological disorder could be explained at a molecular level, the material has often been presented as if the main aim was to illuminate normal neural function. In the present work, the subject of biochemical neurology is presented with the main aim of interpreting in molecular terms, as far as seems possible, the disorders which comprise the content of clinical neurological practice. This approach may lead to a result which may appear unbalanced to the scientific neurochemist, but it may prove more relevant and useful to the clinical neurologist. The latter, looking at familiar clinical facts from a relatively unfamiliar biochemical viewpoint, may gain new insights and become aware of gaps in neurochemical knowledge. Thus research may be stimulated. A chemically-based approach to clinical neurology should include the study of neuromuscular as well as purely neural diseases. Muscle disease is customarily regarded as part of the field of clinical neurology, though there are some major chemical differences between neural and muscular tissue.

To what extent can the content of contemporary clinical neurology be regarded as biochemical? All neural and neuromuscular disorders ultimately involve molecular changes, and all genetic disorders are determined by abnormalities of deoxyribonucleic acids. Therefore it might be argued that the scope of biochemical neurology includes all clinical neurology. However, any attempt at present to deal with all neurological disorders at a biochemical level would show substantial areas for which little biochemical information is available. This book therefore deals only with those neurological conditions where contemporary biochemical knowledge contributes significantly to their understanding. Where the relation between a disorder and a described biochemical abnormality appears too tenuous, e.g. the question of altered central cholinergic neurotransmission in Alzheimer's disease, we have generally felt it inappropriate to discuss the matter, bearing in mind the level at which the book is written. We have also omitted from consideration disorders in which described biochemical abnormalities appear to be purely consequences of a disease process which itself has no known biochemical basis or mechanism. Because of this policy we do not discuss a disorder such as subarachnoid haemorrhage, even though this may lead to clinical biochemical abnormalities, e.g. glycosuria.

Thus we have attempted to write a book interpreting dysfunction of neural and neuromuscular tissues at the molecular level, directed towards the interests of those who investigate and treat such disorders clinically, be they neurologists, physicians, paediatricians, psychiatrists or pathologists. Such an approach may also be of value to laboratory-based neurochemists and biochemists, despite its obvious shortcomings from their point of view.

Throughout the book references have not been supplied to material widely available in standard texts on biochemistry and clinical neurology. Except for recently published work unlikely to have yet been included in the review-type literature, we have preferred to cite reviews of subjects or papers with extensive bibliographies, rather than original research contributions. Thus it is hoped that the reader will be provided with an entry to the relevant literature, without the text becoming unduly cluttered with references.

We are indebted to many persons for help in preparing this book and in particular would wish to express our gratitude to Mrs Janet Wickham for patiently transforming so many pages of largely indecipherable handwriting into a highly professional typescript, to Mr D. Sheehy for drawing the numerous chemical formulae and other illustrations, and to Mr G. Jurrott for photographing them. We would also wish to indicate our thanks to Dr J. Marks, of Girton College, Cambridge, for instigating this project, and to Mr D. Bloomer of MTP Press, for his encouragement and help throughout its course.

M. J. Eadie

J. H. Tyrer

Brisbane

May, 1982

# Contents

## Preface

xi

## 1 The arrangement of the material

1

### 1.1 The approach to the subject

1

### 1.2 The functional significance of certain neurochemical reaction sequences

2

## 2 Disorders of the energy pathway and the metabolic intermediate pool

7

### *Part A: The energy pathway*

7

### 2.1 Disorders of glycogen metabolism

9

#### 2.1.1 Disorders involving accumulation of abnormal polyglycosans

11

##### 2.1.1.1 Corpora amylacea formation

11

##### 2.1.1.2 Lafora body disease

12

#### 2.1.2 Disorders involving impaired catabolism of glycogen

14

##### 2.1.2.1 Acid $\alpha$ -1,4-glucosidase (acid maltase) deficiency: glycogenosis Type II (Pompe's disease)

14

##### 2.1.2.2 Myophosphorylase deficiency (glycogenosis Type V - McArdle's syndrome)

16

##### 2.1.2.3 Other glycogenoses

17

### 2.2 Disorders of Embden-Meyerhof glycolysis

19

#### 2.2.1 Disorders of the proximal direct glycolytic pathway

19

##### 2.2.1.1 Phosphofructokinase deficiency: glycogenosis Type VII

19

##### 2.2.1.2 Hyperglycaemia

20

##### 2.2.1.3 Hypoglycaemia

24

#### 2.2.2 Disorders of fructose metabolism

28

##### 2.2.2.1 Fructose-1,6-diphosphatase deficiency

28

##### 2.2.2.2 Hereditary fructose intolerance

29

#### 2.2.3 Disorders of galactose metabolism

31

##### 2.2.3.1 Galactokinase deficiency

32

##### 2.2.3.2 Galactose-1-phosphate uridyl transferase deficiency: classical galactosaemia

33



2.2.4	Glycerol kinase deficiency	34
2.2.5	Disorders of pyruvate metabolism	34
2.2.5.1	Pyruvate carboxylase deficiency	36
2.2.5.2	Pyruvate dehydrogenase deficiency	37
2.2.5.3	Carnitine acetyltransferase deficiency	39
2.2.5.4	Thiamine deficiency	39
2.2.5.5	Leigh's subacute necrotizing encephalopathy	42
2.3	Disorders of the Krebs cycle	44
2.4	Disorders of mitochondrial electron transport and oxidative phosphorylation	44
2.4.1	Hypoxia	46
2.4.2	Ischaemia	47
<b>Part B: The metabolic intermediate pool</b>		49
2.5	The amino-acid pool and related small molecules	49
2.5.1	Aromatic amino-acid disorders	51
2.5.1.1	Phenylketonuria (hyperphenylalanaemia): phenylalanine hydroxylase deficiency	51
2.5.1.2	Tyrosinaemia	55
2.5.1.3	Hartnup disease	57
2.5.2	Early life ketoacidotic states	60
2.5.2.1	Branched-chain amino-acid disorders (branched-chain ketoaciduria: maple syrup urine disease)	60
2.5.2.2	Hyperglycinaemia	65
2.5.2.2.1	Non-ketotic hyperglycinaemia	66
2.5.2.2.2	Ketotic hyperglycinaemic syndrome	68
2.5.3	Disorders of ammonium metabolism	75
2.5.3.1	Urea cycle defects	76
2.5.3.1.1	Carbamyl phosphate synthetase deficiency	76
2.5.3.1.2	Ornithine transcarbamylase (carbamyl transferase) deficiency	76
2.5.3.1.3	Citrullinaemia	77
2.5.3.1.4	Argininosuccinic acidemia	78
2.5.3.1.5	Hyperargininaemia	79
2.5.3.1.6	Hyperornithinaemia	79
2.5.3.2	Familial lysinuric protein intolerance	79
2.5.3.3	Congenital lysine intolerance with periodic $\text{NH}_4^+$ intoxication	80
2.5.3.4	Other disorders of lysine metabolism	81
2.5.3.5	Further causes of hyperammonaemia	81
2.5.4	Disorders of sulphur-containing amino acids	81
2.5.4.1	Homocystinuria	81
2.5.4.2	Sulphite oxidase deficiency	84

2.5.5	Miscellaneous rare amino-acid disorders	84
2.5.5.1	Disorders of proline metabolism	84
2.5.5.2	Oxoprolinuria	85
2.5.5.3	Histidinaemia	86
2.5.5.4	Carnosinase deficiency	86
2.5.5.5	Homocarnosinase deficiency	87
2.5.5.6	Glutaric acidemia	87
2.6	Disorders of other N-containing small molecules	89
2.6.1	Lesch-Nyhan syndrome	89
2.6.2	Porphyria metabolism disturbances	91
2.6.2.1	Acute intermittent porphyria	92
2.6.2.2	Hereditary coproporphyrinuria	95
2.6.2.3	Variegate porphyria	95
2.6.3	Vitamin deficiencies	95
2.6.3.1	Nicotinic acid deficiency	96
2.6.3.2	Pyridoxine deficiency	97
2.6.3.3	Folate deficiency	100
2.6.3.4	Cobalamin (vitamin B <sub>12</sub> ) deficiency	103
2.6.3.5	Biotin	106
2.6.4	Hepatic encephalopathy	107
2.6.5	Unconjugated bilirubin encephalopathy	111
2.7	Disorders of the intermediary metabolism of fatty acids	112
2.7.1	Carnitine deficiency	113
2.7.2	Carnitine-palmityl transferase deficiency	114
2.7.3	Other disorders of fatty acid metabolism	115
2.8	Disorders of general mitochondrial function	115
2.8.1	Reye's syndrome of toxic encephalopathy with fatty infiltration of the viscera	115
3	Disorders of the metabolism of larger molecules	129
3.1	Disorder of lipid metabolism	131
3.1.1	Disorder of fatty acid composition	134
3.1.1.1	Adrenoleukodystrophy, adrenomyeloneuropathy and Schilder's disease	134
3.1.1.2	Pelizaeus-Merzbacher disease	136
3.1.1.3	Abetalipoproteinaemia	136
3.1.1.4	Phytanic acid accumulation - Refsum's syndrome	137
3.1.2	Sphingolipidoses	142
3.1.2.1	$\beta$ -Galactosidase deficiency (generalized gangliosidosis)	144
3.1.2.2	Hexosaminidase A deficiency (Tay-Sachs disease)	148
3.1.2.3	Total hexosaminidase deficiency (Sandhoff Jackwitz disease; Tay-Sachs variant disease)	150



# CONTENTS

3.1.2.4	Hexoseaminidase B deficiency	151
3.1.2.5	<i>N</i> -acetylgalactoseamine transferase deficiency ( $G_{M3}$ gangliosidosis)	151
3.1.2.6	Ceramide lactoside lipidosis (lactosyl ceramidosis)	152
3.1.2.7	Ceramide trihexoside $\alpha$ -galactosidase deficiency (Fabry's disease)	153
3.1.2.8	Glucocerebroside- $\beta$ -glucosidase deficiency (Gaucher's disease)	154
3.1.2.9	Arylsulphatase A deficiency (metachromatic leukodystrophy)	156
3.1.2.10	Multiple sulphatase deficiency	158
3.1.2.11	Galactocerebroside- $\beta$ -galactosidase deficiency (Krabbe's globoid cell leukodystrophy)	158
3.1.2.12	Sphingomyelinase deficiency (Niemann-Pick disease)	160
3.2	Glycosaminoglycan disorders: the mucopolysaccharidoses	161
3.2.1	$\alpha$ -L-Iduronidase deficiency (Hurler's disease)	164
3.2.2	$\alpha$ -L-Iduronidase partial deficiency (Scheie's syndrome)	166
3.2.3	$\alpha$ -L-Iduronidase deficiency (mixed Hurler-Scheie type)	167
3.2.4	$\alpha$ -L-Iduronylsulphate sulphatase deficiency (Hunter's disease)	167
3.2.5	Sulphamidase deficiency (Sanfillipo A disease)	169
3.2.6	$\alpha$ - <i>N</i> -Acetylglucosaminidase deficiency (Sanfillipo B disease)	170
3.2.7	Acetyl CoA ( $\alpha$ -glucosaminidase- <i>N</i> -acetyl transferase) deficiency (Sanfillipo C disease)	171
3.2.8	<i>N</i> -Acetylhexosamine-6-sulphate sulphatase deficiency (Morquio's disease)	171
3.2.9	Arylsulphatase B deficiency (Maroteaux-Lamy syndrome)	171
3.2.10	$\beta$ -Glucuronidase deficiency	173
3.3	The mucolipidoses	173
3.3.1	$\alpha$ -Mannosidase deficiency: mannosidosis	176
3.3.2	$\alpha$ -Fucosidase deficiency: fucosidosis	177
3.3.3	Aspartylglucosaminuria	178
3.3.4	Multiple sulphatase deficiency: juvenile sulphatidosis	179
3.3.5	Mucolipidosis II: I-cell disease	180
3.3.6	Mucolipidosis III	181
3.4	$\alpha$ - <i>N</i> -Acetyl neuraminidase deficiency: sialidosis	182
3.5	The ceroid lipofuscinoses	184
3.6	Disorders of protein composition	186
3.6.1	Amyloidosis	186

<b>4 Disorders involving inorganic ions</b>	<b>193</b>
4.1 $\text{Na}^+$	193
4.1.1 Hyponatraemia and hypo-osmolality	193
4.1.2 Hypernatraemia	196
4.2 $\text{K}^+$	197
4.2.1 Hypokalaemia	197
4.2.2 Hyperkalaemia	200
4.3 $\text{Ca}^{2+}$	201
4.3.1 Hypocalcaemia	201
4.3.2 Hypercalcaemia	203
4.4 $\text{Mg}^{2+}$	204
4.4.1 Hypomagnesaemia	204
4.4.2 Hypermagnesaemia	205
4.5 $\text{H}^+$	206
4.5.1 Acidosis	206
4.5.2 Alkalosis	208
4.6 Copper	210
4.6.1 Copper toxicity: Wilson's disease	210
4.6.2 Copper deficiency: Menkes' kinky hair disease	211
4.7 Ammonium	212
4.8 Uraemia	212
<b>5 Disturbances of synaptic transmission</b>	<b>217</b>
5.1 Principles of neurotransmitter biology	217
5.2 Acetylcholine	220
5.2.1 Acetylcholine biology	220
5.2.2 Disorders related to altered acetylcholine function	221
5.2.2.1 Myasthenia gravis	222
5.2.2.2 Myasthenic syndrome (Eaton-Lambert syndrome)	224
5.2.2.3 Pseudocholinesterase deficiency	225
5.3 Catecholamines	226
5.3.1 Catecholamine biology	226
5.3.2 Disorders related to altered catecholamine function	230
5.3.2.1 Striatal dopamine deficiency: Parkinson's disease	230
5.3.2.2 Striatal dopamine excess: chorea	233
5.3.2.3 Tardive dyskinesia	235
5.3.2.4 Other dyskinesias related to dopamine dysfunction	236
5.3.2.5 Mieg's disease	237
5.3.2.6 Dopamine and schizophrenia	237
5.3.2.7 Noradrenaline and affective illness	237
5.3.2.8 Essential tremor	240
5.4 Serotonin	240
5.4.1 Serotonin biology	240

# CONTENTS

5.4.2	Diseases related to altered serotonin function	242
5.4.2.1	Depression	242
5.4.2.2	Sleep disorders	242
5.4.2.3	Myoclonus	243
5.4.2.4	Epilepsy	244
5.4.2.5	Migraine	244
5.4.2.6	Migrainous neuralgia: cluster headache	248
5.5	$\gamma$ -Aminobutyric acid	248
5.5.1	$\gamma$ -Aminobutyrate biology	248
5.5.2	Diseases related to altered $\gamma$ -aminobutyrate function	250
5.6	Disorders involving glycine function	251
Index		255

# 1 The arrangement of the material

---

In writing for clinicians, it is difficult to know how much biochemical detail to present, and what basic knowledge of chemistry to assume. Generally in this book we have tried to give only enough chemistry to show the reader the structures of the various molecules considered and to follow the different chemical reaction sequences discussed. Reaction mechanisms as such have not been considered. Illustration devices such as shading have been used to allow the reader's eye to follow the fates of relevant portions of molecules more easily, and to emphasize aspects of molecular structure which are pertinent in particular contexts. We have assumed relatively little background chemical knowledge on the part of the reader, though we realize this policy may irritate those chemically more sophisticated. For simplicity we have often not followed all the ramifications of a particular chemical reaction at the one time, but have concentrated on those aspects germane to the disturbance currently under discussion. However, we have attempted by cross-referencing to bring out the interrelations between the various reactions of the one molecule which can yield different chemical products and be responsible for different diseases. Thus it is hoped that material presented as individual chemical facets can later be synthesized by the reader into a biochemical overview.

The material has been arranged around a concept of biochemical functioning of nervous tissue in a way which it is hoped may be relevant to the clinician, but which may appear unconventional and perhaps inappropriate to the biochemist. We have tried to fit the individual biochemical neurological disorders into this arrangement, even when the fit has sometimes not been a particularly comfortable one, because we wished to present the individual disturbances in relation to an over-riding concept of neurochemical function, rather than describing the disorders as a series of self-contained and sometimes apparently unrelated chemical entities.

## 1.1 THE APPROACH TO THE SUBJECT

It seemed possible to deal with biochemical neurology in two main ways. First,


we could follow the conventional biochemist's method of considering in turn the various classes of molecule found in neural tissue and muscle, and then discuss the neurological disorders associated with disturbed metabolism of each of these classes of molecule. Secondly, we could take the various diseases in the order in which they are dealt with in most textbooks of clinical neurology, and describe the abnormal chemistry of each condition in turn. The latter approach had the advantage that the book's intended reader, the clinician, would move from the more familiar to the less familiar. He would see the chemistry in relation to clinical data that he already knew. Unfortunately, however, it would mean that chemically unrelated conditions might be dealt with side by side, and chemically related conditions might be divorced. It would therefore be more difficult to develop any comprehensive view of normal and abnormal neurochemistry, unless what might appear to the clinician as an indigestible and doubtfully relevant body of normal neurochemistry were presented first, and the diseases were then considered seriatim as in textbooks of clinical neurology. To avoid this undesirable arrangement we have dealt with neurological disease in an order that has been determined chiefly by chemical considerations. We believe this approach allows the greater opportunity for the clinician to develop chemical insights. However, we have not simply taken chemical class as the primary criterion for determining the order in which neurological diseases are considered. Rather, we have seen in the complex patterns of chemical activities that occur in cells, groupings of reactions that serve particular functional purposes that appear especially germane to the interests of clinical neurology. We have built the book around an analysis of disorders of these functional biochemical reaction sequences (which, to a considerable extent, do correlate with chemical class).

## 1.2 THE FUNCTIONAL SIGNIFICANCE OF CERTAIN NEUROCHEMICAL REACTION SEQUENCES


The nervous system is chiefly concerned with the rapid transmission of signals from point to point within the body. This transmission involves electrical conduction along preformed anatomical pathways which are kept in a state of excitability, and also chemical transmission across synaptic clefts between nerve cells and, at the periphery, between nerve cells and effector cells. One can conceive the main biochemical functions of neural tissue as involving the production of energy, required to drive chemical reactions serving various purposes, including:

- (1) The synthesis and degradation of large molecules, required to maintain the structural integrity on which the function of neural tissue depends,
- (2) The production of ionic concentration gradients, required to sustain nerve cell excitability, and
- (3) The maintenance of the synaptic transmission process.

In addition, there are reactions of small metabolic intermediate molecules involved in various synthetic activities. The energy yielding reaction sequence and the reaction of small metabolic intermediate molecules are so intimately linked that they are conveniently considered together. Thus the functional concept



may be correlated with a concept of neurochemical processes.




Such a schematic overview embraces many important aspects of neural activity, though it does not bring out the mutual interdependence of the various processes. When one considers skeletal muscle function, certain different macromolecules become relevant, the whole matter of synaptic transmission is largely inapplicable, and high energy phosphate ( $\sim P$ ) use is heavily directed towards muscle contraction rather than towards impulse conduction.

In this book, the disorders to be considered have been grouped according to which of the major neurochemical functions is primarily disturbed in each disorder. A disorder may, of course, produce consequent disturbance of biochemical mechanisms in a different functional category or categories, and the primary disturbance of molecular mechanisms (usually an enzyme defect) may not always be known with certainty. Consequently the classification of disorders here adopted may not prove valid in all instances, as knowledge grows.

It may now be useful to amplify to a limited extent the more important chemical reaction sequences involved in the major groups of neurological functions mentioned in Figure 1.1. These reaction sequences determine the subdivision of the contents of the various chapters of this book. In general, for each subdivision (i.e. a major group of related reactions) we have attempted to provide an initial account of the chemistry in sufficient detail for the clinician's purposes. We have then related known neurological disorders to this chemistry, attempting to emphasize principles and features common to a group of disorders, where possible. Then individual clinical disorders of each reaction sequence are dealt with briefly, but in a systematic fashion, under the





**Figure 1.1** Major aspects of neurochemical activity, with the relevant chemical pathways (in outline)

following subheadings, unless the available material is too slight to warrant such subdivision:

- (1) Introductory comment,
- (2) Biochemical abnormality,
- (3) Aetiology,
- (4) Structural pathology,
- (5) Clinical features,
- (6) Diagnosis
  - (a) clinical
  - (b) laboratory,
- (7) Treatment.



